Risk adjusted net present value: What is the current valuation of TScan Therapeutics’s TSC-200-A0201?

TSC-200-A0201 is a gene-modified cell therapy commercialized by TScan Therapeutics, with a leading Phase I program in Metastatic Ovarian Cancer.

Could your daily routine lead to dementia? New research points to sedentary lifestyle as potential risk factor

In a recent study, researchers investigated whether accelerometer-assessed sedentary behavior was associated with incident dementia.

September 13, 2023

RLDatix Acquires SocialClimb: Expanding Healthcare Operations

What You Should Know: – RLDatix, a global leader in connected healthcare operations software and services, has announced its acquisition of SocialClimb, a healthcare technology

September 19, 2024

RNA enzyme found key to heart cell energy shift after birth

Researchers investigate the influence of Mettl1 on energy metabolism and the maturation of heart cells after birth.

November 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.